Argenta Discovery Limited, the respiratory drug discovery and development company, and Dr. Reddy's Laboratories (NYSE:RDY), announce a major milestone in their development programme targeting a novel disease-modifying approach to treat the underlying cause of certain chronic respiratory diseases including chronic obstructive pulmonary disease (COPD) and severe asthma. Argenta's Chief Executive Officer, Dr. Christopher Ashton said: "Just 18 months after signing the deal with Dr. [click link for full article]
(more...)